Bi-CAR-T (Product #2)

About Bio4t2

Bio4t2 is pioneering a multi-technology platform approach to overcome the historic challenges of applying CAR-T therapy to solid tumors. Its core PrismCore platform generates CARs with antigen-density-dependent activation, aiming to selectively target tumors while sparing healthy tissue. The company's lead asset, B4t2-001, is in clinical testing, and its pipeline includes a next-generation bispecific Bi-CAR-T product. Bio4t2's innovations in engraftment without preconditioning chemotherapy and integrated safety controls position it as a potential disruptor in the solid tumor cell therapy space.

Therapeutic Areas

Other Solid tumors (unspecified) Drugs